Cargando…
Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(®)): a global review
RABORAL V-RG(®) is an oral rabies vaccine bait that contains an attenuated (“modified-live”) recombinant vaccinia virus vector vaccine expressing the rabies virus glycoprotein gene (V-RG). Approximately 250 million doses have been distributed globally since 1987 without any reports of adverse reacti...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610451/ https://www.ncbi.nlm.nih.gov/pubmed/28938920 http://dx.doi.org/10.1186/s13567-017-0459-9 |
_version_ | 1783265781700624384 |
---|---|
author | Maki, Joanne Guiot, Anne-Laure Aubert, Michel Brochier, Bernard Cliquet, Florence Hanlon, Cathleen A. King, Roni Oertli, Ernest H. Rupprecht, Charles E. Schumacher, Caroline Slate, Dennis Yakobson, Boris Wohlers, Anne Lankau, Emily W. |
author_facet | Maki, Joanne Guiot, Anne-Laure Aubert, Michel Brochier, Bernard Cliquet, Florence Hanlon, Cathleen A. King, Roni Oertli, Ernest H. Rupprecht, Charles E. Schumacher, Caroline Slate, Dennis Yakobson, Boris Wohlers, Anne Lankau, Emily W. |
author_sort | Maki, Joanne |
collection | PubMed |
description | RABORAL V-RG(®) is an oral rabies vaccine bait that contains an attenuated (“modified-live”) recombinant vaccinia virus vector vaccine expressing the rabies virus glycoprotein gene (V-RG). Approximately 250 million doses have been distributed globally since 1987 without any reports of adverse reactions in wildlife or domestic animals since the first licensed recombinant oral rabies vaccine (ORV) was released into the environment to immunize wildlife populations against rabies. V-RG is genetically stable, is not detected in the oral cavity beyond 48 h after ingestion, is not shed by vaccinates into the environment, and has been tested for thermostability under a range of laboratory and field conditions. Safety of V-RG has been evaluated in over 50 vertebrate species, including non-human primates, with no adverse effects observed regardless of route or dose. Immunogenicity and efficacy have been demonstrated under laboratory and field conditions in multiple target species (including fox, raccoon, coyote, skunk, raccoon dog, and jackal). The liquid vaccine is packaged inside edible baits (i.e., RABORAL V-RG, the vaccine-bait product) which are distributed into wildlife habitats for consumption by target species. Field application of RABORAL V-RG has contributed to the elimination of wildlife rabies from three European countries (Belgium, France and Luxembourg) and of the dog/coyote rabies virus variant from the United States of America (USA). An oral rabies vaccination program in west-central Texas has essentially eliminated the gray fox rabies virus variant from Texas with the last case reported in a cow during 2009. A long-term ORV barrier program in the USA using RABORAL V-RG is preventing substantial geographic expansion of the raccoon rabies virus variant. RABORAL V-RG has also been used to control wildlife rabies in Israel for more than a decade. This paper: (1) reviews the development and historical use of RABORAL V-RG; (2) highlights wildlife rabies control programs using the vaccine in multiple species and countries; and (3) discusses current and future challenges faced by programs seeking to control or eliminate wildlife rabies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13567-017-0459-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5610451 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56104512017-10-10 Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(®)): a global review Maki, Joanne Guiot, Anne-Laure Aubert, Michel Brochier, Bernard Cliquet, Florence Hanlon, Cathleen A. King, Roni Oertli, Ernest H. Rupprecht, Charles E. Schumacher, Caroline Slate, Dennis Yakobson, Boris Wohlers, Anne Lankau, Emily W. Vet Res Review RABORAL V-RG(®) is an oral rabies vaccine bait that contains an attenuated (“modified-live”) recombinant vaccinia virus vector vaccine expressing the rabies virus glycoprotein gene (V-RG). Approximately 250 million doses have been distributed globally since 1987 without any reports of adverse reactions in wildlife or domestic animals since the first licensed recombinant oral rabies vaccine (ORV) was released into the environment to immunize wildlife populations against rabies. V-RG is genetically stable, is not detected in the oral cavity beyond 48 h after ingestion, is not shed by vaccinates into the environment, and has been tested for thermostability under a range of laboratory and field conditions. Safety of V-RG has been evaluated in over 50 vertebrate species, including non-human primates, with no adverse effects observed regardless of route or dose. Immunogenicity and efficacy have been demonstrated under laboratory and field conditions in multiple target species (including fox, raccoon, coyote, skunk, raccoon dog, and jackal). The liquid vaccine is packaged inside edible baits (i.e., RABORAL V-RG, the vaccine-bait product) which are distributed into wildlife habitats for consumption by target species. Field application of RABORAL V-RG has contributed to the elimination of wildlife rabies from three European countries (Belgium, France and Luxembourg) and of the dog/coyote rabies virus variant from the United States of America (USA). An oral rabies vaccination program in west-central Texas has essentially eliminated the gray fox rabies virus variant from Texas with the last case reported in a cow during 2009. A long-term ORV barrier program in the USA using RABORAL V-RG is preventing substantial geographic expansion of the raccoon rabies virus variant. RABORAL V-RG has also been used to control wildlife rabies in Israel for more than a decade. This paper: (1) reviews the development and historical use of RABORAL V-RG; (2) highlights wildlife rabies control programs using the vaccine in multiple species and countries; and (3) discusses current and future challenges faced by programs seeking to control or eliminate wildlife rabies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13567-017-0459-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-22 2017 /pmc/articles/PMC5610451/ /pubmed/28938920 http://dx.doi.org/10.1186/s13567-017-0459-9 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Maki, Joanne Guiot, Anne-Laure Aubert, Michel Brochier, Bernard Cliquet, Florence Hanlon, Cathleen A. King, Roni Oertli, Ernest H. Rupprecht, Charles E. Schumacher, Caroline Slate, Dennis Yakobson, Boris Wohlers, Anne Lankau, Emily W. Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(®)): a global review |
title | Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(®)): a global review |
title_full | Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(®)): a global review |
title_fullStr | Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(®)): a global review |
title_full_unstemmed | Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(®)): a global review |
title_short | Oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG(®)): a global review |
title_sort | oral vaccination of wildlife using a vaccinia–rabies-glycoprotein recombinant virus vaccine (raboral v-rg(®)): a global review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610451/ https://www.ncbi.nlm.nih.gov/pubmed/28938920 http://dx.doi.org/10.1186/s13567-017-0459-9 |
work_keys_str_mv | AT makijoanne oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT guiotannelaure oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT aubertmichel oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT brochierbernard oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT cliquetflorence oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT hanloncathleena oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT kingroni oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT oertliernesth oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT rupprechtcharlese oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT schumachercaroline oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT slatedennis oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT yakobsonboris oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT wohlersanne oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview AT lankauemilyw oralvaccinationofwildlifeusingavacciniarabiesglycoproteinrecombinantvirusvaccineraboralvrgaglobalreview |